| First Author | Lu Y | Year | 2018 |
| Journal | Cancer Cell | Volume | 33 |
| Issue | 6 | Pages | 1048-1060.e7 |
| PubMed ID | 29894691 | Mgi Jnum | J:262543 |
| Mgi Id | MGI:6162279 | Doi | 10.1016/j.ccell.2018.05.004 |
| Citation | Lu Y, et al. (2018) Th9 Cells Represent a Unique Subset of CD4(+) T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 33(6):1048-1060.e7 |
| abstractText | The antitumor effector T helper 1 (Th1) and Th17 cells represent two T cell paradigms: short-lived cytolytic Th1 cells and "stem cell-like" memory Th17 cells. We report that Th9 cells represent a third paradigm-they are less-exhausted, fully cytolytic, and hyperproliferative. Only tumor-specific Th9 cells completely eradicated advanced tumors, maintained a mature effector cell signature with cytolytic activity as strong as Th1 cells, and persisted as long as Th17 cells in vivo. Th9 cells displayed a unique Pu.1-Traf6-NF-kappaB activation-driven hyperproliferative feature, suggesting a persistence mechanism rather than an antiapoptotic strategy. Th9 antitumor efficacy depended on interleukin-9 and upregulated expression of Eomes and Traf6. Thus, tumor-specific Th9 cells are a more effective CD4(+) T cell subset for adoptive cancer therapy. |
